Groowe Groowe / Newsroom / NBIX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

NBIX News

Neurocrine Biosciences Inc

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

globenewswire.com
TLRY TAK TNDM NVS BMY PFE INCY JNJ AZN MRK ABBV CRSP SCLX RIGL JAZZ GILD REGN AMGN BIIB PTGX EXAS SNOW SRPT VRTX BNTX ALKS RGEN IMUX ADPT ATRC CRNX CYTK DTIL EXEL FGEN GALT GNTX GRFS GSK HRMY IDXX ILMN INSM IONS IRWD KODK LAKE LULU LYFT MAR MDLZ MELI MIRM MNKD MRNA MTCH NBIX NCLH NEM NTRA NVCR ODFL OMER ORGO OTEX PACB PBYI PCAR PEGA PERI PETS PLRX PMVP PPC PRGS PRTA PSNL PTN PZZA QGEN QTRX RARE RCEL RDHL RLAY RLGT RMD ROST RRX RYAAY RYTM SAN SBAC SBRA SEIC SIGA SIRI SITE SLAB SLGN SMCI SMMT SNPS SNY SOFI SONO SPCE SSYS STNG STRA STRL STX SWKS SYK SYNA TCOM TDOC TECK TEVA TFX TGTX TIGR TRMB TRVG TTWO TUSK TXRH ULTA UMC UNFI UNH URBN UTHR VEEV VELO VERU VIVO VKTX VLRS VNDA VRSK VSAT VTGN WDC WEC WERN WGO WIX WMB WST WTW WYNN XOM XPER XPO XRAY YETI YRD YUM ZBRA ZLAB ZYME

Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight

prnewswire.com
NBIX

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

prnewswire.com
NBIX

Global Huntington's Disease Treatment Market 2026-2031 - Advancements in Novel Therapeutics to Drive Growth

globenewswire.com
PFE TEVA NBIX ALNY IONS NVS QURE SANG PTC WVE

Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight

globenewswire.com
BIIB HRMY XNCR AZN LLY PFE REGN NVS TSLA TAK GSK JNJ UCB BHF PRAX XENE AQST TNDM INCY MRK ABBV BMY AMGN GILD VRTX CRSP EDIT NTLA SRPT ALNY EXAS TEVA AXSM CYTK INSM KODK LPCN MNKD NBIX NCLH ONCY ORIC PBYI PEGA PLRX PRGS QGEN RGNX ROST RYAAY SNOW SWKS SYK TGT TRMB TXG ULTA VRSK WDC WVE XOM ZBRA ZNTL ZTS STOK IONS MOMO BBAR CTXR MBIO GNS NEON OVID BHVN

Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors

prnewswire.com
ACRS ALC AMGN BCRX BIIB BMY CRSP CTRA CYTK DASH EXAS GILD GSK INCY JNJ KDP LULU MRNA NBIX NVS OCGN ORCL PFE REGN ROST RVMD SNOW SRPT STRL TGTX TMO TRMB TSLA TXG VRTX XOM ZBRA

Atsena Therapeutics Appoints Matt Pauls to Board of Directors

globenewswire.com
SVRA NBIX JNJ

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

prnewswire.com
NBIX

Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight

globenewswire.com
NVO LLY BMY AXSM JNJ SNY BIIB ABBV MRK REGN GILD AMGN AZN TEVA BHC ALKS VRTX SRPT CRIS NTLA EDIT INCY ACAD ALNY CYTK IONS EXAS IDXX VNDA SUPN RGNX XOM CVAC BNTX ARCT MRNA NBIX ADPT AVXL IMUX PRGS RDNT CRDF ADSK ANAB ATRC CLDX CPRX ESPR EXEL FGEN GALT GRFS HRMY IGC INSM KODK LAKE LCTX LEXX LPCN MESO MITK MNKD MSFT MYGN NEO NVCR NXPI OCGN OMER ORCL PACB PFE PLRX PRGO PSNL PTGX QGEN RARE ROST RVMD SEIC SIGA SMCI SNOW SOFI SPRO TGTX TNDM TXG ULTA VEEV VKTX VRNS WVE XRAY ZBRA ZNTL

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

prnewswire.com
NBIX